Activation of Notch1 signaling in podocytes by glucose-derived AGEs contributes to proteinuria.
advanced glycation end product
kidney/glomerulus/pathology
notch
proteinuria
Journal
BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
17
01
2020
revised:
24
04
2020
accepted:
26
05
2020
entrez:
1
7
2020
pubmed:
1
7
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Advanced glycation end-products (AGEs) are implicated in the pathogenesis of diabetic nephropathy (DN). Previous studies have shown that AGEs contribute to glomerulosclerosis and proteinuria. Podocytes, terminally differentiated epithelial cells of the glomerulus and the critical component of the glomerular filtration barrier, express the receptor for AGEs (RAGE). Podocytes are susceptible to severe injury during DN. In this study, we investigated the mechanism by which AGEs contribute to podocyte injury. Glucose-derived AGEs were prepared in vitro. Reactivation of Notch signaling was examined in AGE-treated human podocytes (in vitro) and glomeruli from AGE-injected mice (in vivo) by quantitative reverse transcription-PCR, western blot analysis, ELISA and immunohistochemical staining. Further, the effects of AGEs on epithelial to mesenchymal transition (EMT) of podocytes and expression of fibrotic markers were evaluated. Using human podocytes and a mouse model, we demonstrated that AGEs activate Notch1 signaling in podocytes and provoke EMT. Inhibition of RAGE and Notch1 by FPS-ZM1 (N-Benzyl-4-chloro-N-cyclohexylbenzamide) and DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenyl glycine t-butylester), respectively, abrogates AGE-induced Notch activation and EMT. Inhibition of RAGE and Notch1 prevents AGE-induced glomerular fibrosis, thickening of the glomerular basement membrane, foot process effacement, and proteinuria. Furthermore, kidney biopsy sections from people with DN revealed the accumulation of AGEs in the glomerulus with elevated RAGE expression and activated Notch signaling. The data suggest that AGEs activate Notch signaling in the glomerular podocytes. Pharmacological inhibition of Notch signaling by DAPT ameliorates AGE-induced podocytopathy and fibrosis. Our observations suggest that AGE-induced Notch reactivation in mature podocytes could be a novel mechanism in glomerular disease and thus could represent a novel therapeutic target.
Identifiants
pubmed: 32601154
pii: 8/1/e001203
doi: 10.1136/bmjdrc-2020-001203
pmc: PMC7326296
pii:
doi:
Substances chimiques
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Am J Physiol Renal Physiol. 2016 Nov 1;311(5):F831-F843
pubmed: 27582102
Korean J Physiol Pharmacol. 2014 Feb;18(1):1-14
pubmed: 24634591
Diabetes. 2006 Jan;55(1):225-33
pubmed: 16380497
J Am Soc Nephrol. 2000 Sep;11(9):1656-66
pubmed: 10966490
Kidney Int. 2004 Sep;66(3):1167-72
pubmed: 15327413
Nat Med. 2008 Mar;14(3):290-8
pubmed: 18311147
J Clin Invest. 2014 Mar;124(3):1098-113
pubmed: 24531545
J Cell Mol Med. 2017 Dec;21(12):3435-3444
pubmed: 28643424
J Cell Physiol. 2019 May;234(5):6503-6518
pubmed: 30238984
Development. 2003 Oct;130(20):5031-42
pubmed: 12952904
Arch Biochem Biophys. 2016 Jan 15;590:10-19
pubmed: 26550927
Development. 2017 Dec 15;144(24):4530-4539
pubmed: 29113990
Front Endocrinol (Lausanne). 2013 Feb 06;4:7
pubmed: 23390421
Semin Nephrol. 2012 Jul;32(4):385-93
pubmed: 22958493
Diabetes. 2013 Sep;62(9):3241-50
pubmed: 23630304
J Biol Chem. 2019 Nov 1;294(44):16109-16122
pubmed: 31511328
Kidney Int Suppl (2011). 2014 Nov;4(1):65-69
pubmed: 26312152
J Clin Endocrinol Metab. 2008 Apr;93(4):1143-52
pubmed: 18182449
Curr Opin Nephrol Hypertens. 2014 Nov;23(6):547-54
pubmed: 25160075
Nephrol Dial Transplant. 2007 Oct;22(10):3093-4
pubmed: 17597090
Rev Endocr Metab Disord. 2008 Dec;9(4):245-54
pubmed: 18726161
Chem Biol Interact. 2014 Oct 5;222:68-76
pubmed: 25199697
J Surg Res. 2011 Dec;171(2):871-6
pubmed: 20638679
Front Endocrinol (Lausanne). 2014 Oct 01;5:148
pubmed: 25324828
Nephron Exp Nephrol. 2009;111(4):e73-9
pubmed: 19293596
J Biol Chem. 2007 Apr 20;282(16):11969-81
pubmed: 17317671
Diabetes. 2005 Nov;54(11):3103-11
pubmed: 16249432
J Am Soc Nephrol. 2015 Aug;26(8):1939-59
pubmed: 25424328
Dermatoendocrinol. 2012 Jul 1;4(3):259-70
pubmed: 23467327
Kidney Int. 2005 Nov;68(5):1951-2
pubmed: 16221173
Am J Pathol. 2004 Dec;165(6):2033-43
pubmed: 15579446
Am J Physiol Renal Physiol. 2003 Jul;285(1):F40-8
pubmed: 12631553
PLoS One. 2013 Nov 07;8(11):e80328
pubmed: 24244677
Curr Opin Nephrol Hypertens. 2011 Jan;20(1):56-61
pubmed: 21088575
Ren Fail. 2017 Nov;39(1):474-483
pubmed: 28413908
Semin Nephrol. 2016 May;36(3):208-19
pubmed: 27339386
Nephrol Dial Transplant. 2007 Mar;22(3):722-31
pubmed: 17192279
F1000Res. 2016 Jan 28;5:
pubmed: 26918173
Adv Chronic Kidney Dis. 2014 Sep;21(5):408-16
pubmed: 25168829
J Am Soc Nephrol. 2008 Jun;19(6):1139-57
pubmed: 18337488
Diabetes Res Clin Pract. 2010 Feb;87(2):167-75
pubmed: 19969384
N Engl J Med. 1988 May 19;318(20):1315-21
pubmed: 3283558
J Clin Invest. 2010 Nov;120(11):4040-54
pubmed: 20978353
Oxid Med Cell Longev. 2010 Mar-Apr;3(2):101-8
pubmed: 20716934
Hepatology. 2018 Jun;67(6):2226-2243
pubmed: 29171033
Biomol Concepts. 2016 Dec 1;7(5-6):293-309
pubmed: 27816946